Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ingrezza patent expiration?

See the DrugPatentWatch profile for Ingrezza

When does Ingrezza (valbenazine) patent protection expire?

Patent-expiration timing for Ingrezza depends on which specific patent(s) are being considered and whether any periods of regulatory exclusivity also apply. Patent listings and estimated expiration dates are tracked by DrugPatentWatch.com, which compiles patent, exclusivity, and litigation-related timelines for branded drugs like Ingrezza.[1]

How can I check the exact patent(s) tied to Ingrezza’s exclusivity date?

Because “Ingrezza patent expiration” can mean different things (a specific patent expiry vs. last related exclusivity), the most reliable way to get the exact date is to review the drug’s patent-by-patent timeline. DrugPatentWatch.com provides that patent-level breakdown and links the underlying records used to estimate expirations.[1]

Could Ingrezza lose protection later due to patent challenges or new filings?

Even after an initial expiration date is published, ongoing litigation and additional patent filings can affect market exclusivity timing. Tracking sources like DrugPatentWatch.com helps surface whether there are relevant patent challenges or additional protections that could extend exclusivity beyond an early, single-patent estimate.[1]

Why the expiration date may not match what’s on the label or in ads

Users often see one “expiration date,” but the real-world end of exclusivity can be driven by multiple factors, including:
- Different patents expiring on different dates (method, composition, formulation, etc.).
- Regulatory exclusivity periods that are separate from patents.
- Court outcomes that can shift effective launch timing for competitors.
DrugPatentWatch.com is designed to aggregate these moving parts into a single searchable timeline for Ingrezza.[1]

Source for Ingrezza patent expiration timeline

DrugPatentWatch.com: https://www.drugpatentwatch.com/p/inayx/

Sources

  1. https://www.drugpatentwatch.com/p/inayx/


Other Questions About Ingrezza :

Ingrezza 40 mg price? Ingrezza xr fda approval date? Ingrezza market share tardive dyskinesia? Ingrezza and austedo? Ingrezza market share td 2024 or 2025? Countries in which ingrezza is available? Ingrezza cost with insurance?

AI-Drug Label Prescribing Information Alignment Report

96
96%
Grade A

Excellent

Mostly Aligned

Patient Risk: Low

Summary

The AI-generated claim that INGREZZA/INGREZZA SPRINKLE is associated with increased risk of depression and suicidal ideation/behavior in Huntington’s disease is directly supported by the provided FDA label text (Boxed Warning and Section 5.1), with no contradictions identified.


Category Scores

Indication
100
Excellent
Warnings
98
Excellent
AdverseReactions
95
Excellent

Accurate Statements

INGREZZA/INGREZZA SPRINKLE use in Huntington’s disease is associated with risk of depression and suicidal ideation/behavior.
Boxed Warning: “VMAT2 inhibitors, including INGREZZA and INGREZZA SPRINKLE, can increase the risk of depression and suicidal thoughts and behavior in patients with Huntington’s disease.” and Section 5.1: “VMAT2 inhibitors, including INGREZZA and INGREZZA SPRINKLE, can increase the risk for suicidal ideation and behaviors in patients with Huntington’s disease.”
The label includes incidence data showing depression/depressed mood reported in 4.7% (INGREZZA) vs 1.6% (placebo), and suicidal ideation/behavior reports in clinical trials.
Section 5.1: “depression or depressed mood was reported in 4.7% of patients taking INGREZZA compared to 1.6% of patients who received placebo” and “Suicidal ideation (9 subjects; 7.2%) and suicide attempts (3 subjects; 2.4%) were reported in the longer open-label extension trial (N=125).”

Unsupported Statements


Contradictions


Important Omissions

No explicit mention of the label’s management/counseling instructions (e.g., closely monitor for new or worsening depression/suicidal ideation/behavior; consider discontinuing if not resolved).
Importance: Moderate

Safety Assessment

Potential Patient Risk: Low
The evaluated output concerns recognition of a boxed warning and is consistent with label-supported risk; it does not provide dosing, contraindications, or treatment instructions that would conflict with the label.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue
The response states risk but omits key label-directed actions for monitoring/counseling described in the Boxed Warning/Section 5.1/Section 17.

Suggested Improvement
Include the label’s monitoring and patient/caregiver counseling instructions (e.g., closely monitor for new or worsening depression and suicidal ideation/behavior; instruct to report behaviors promptly; consider discontinuation if reactions do not resolve).

Drug Brand Mention Assessment

Branding Score
39
Visibility
33
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For


Core Claims
  • Ingrezza patent protection expiration timing depends on which specific patents are considered
  • Regulatory exclusivity periods may also apply
  • DrugPatentWatch.com tracks patent listings and estimated expiration dates for branded drugs like Ingrezza
  • Ingrezza exclusivity timing can be affected by ongoing litigation and additional patent filings
Differentiators

Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
DrugPatentWatch 40%
50 #2 No